Mounjaro (Tirzepatide)

Tirzepatide, the active ingredient in Mounjaro, is a dual GIP and GLP‑1 receptor agonist presented as a solution for injection for subcutaneous use. It treats type 2 diabetes mellitus and is also indicated for weight management in adults.

GNH USA supplies Mounjaro as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mounjaro (tirzepatide) is used in the management of metabolic disorders, primarily targeting glucose regulation and body weight.

- Type 2 diabetes mellitus: improves glycemic control and reduces HbA1c levels. - Obesity (weight management): promotes clinically significant weight loss through appetite reduction. - Overweight with comorbidities: assists patients in achieving weight‑loss goals when combined with diet and exercise.

Common Side Effects: - Nausea - Vomiting - Diarrhea - Constipation - Decreased appetite - Injection‑site reactions

Serious or Rare Side Effects: - Pancreatitis - Severe hypoglycemia (especially with concomitant insulin or sulfonylureas) - Gallbladder disease (e.g., cholelithiasis) - Allergic reactions including anaphylaxis - Thyroid C‑cell tumors (observed in rodent studies) - Acute renal impairment

Before initiating tirzepatide therapy, consider the following precautions: - Renal function assessment: adjust use in patients with severe renal impairment. - Pancreatitis monitoring: discontinue if signs of pancreatitis develop. - Thyroid history: avoid in individuals with a personal or family history of medullary thyroid carcinoma or MEN 2. - Hypoglycemia risk: reduce doses of concomitant insulin or sulfonylureas to prevent severe low blood glucose. - Gastrointestinal disease: use cautiously in patients with severe gastroparesis. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Tirzepatide may interact with other medicines as follows:

Major Interactions (Avoid): - Insulin or sulfonylureas: increased risk of severe hypoglycemia. - Other GLP‑1 receptor agonists: additive gastrointestinal adverse effects. - Medications associated with pancreatitis: may amplify pancreatitis risk.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of INR, monitor coagulation parameters. - Diuretics: monitor renal function and electrolytes. - Oral contraceptives: possible reduced efficacy, observe for breakthrough bleeding.